

Ovarian

Non-Metastatic, Newly Diagnosed or Recurrent Disease (somatic)

When and what should be tested?

- Treatment eligible
- All patients with non-metastatic disease
- Performance status of ECOG 0-2
- At initial diagnosis or upon progression
- Patients with hereditary risk syndromes
- Tissue sample preferred
- Consider liquid biopsy if lack of tissue

FDA/NCCN approved

- Germline mutation testing
 - BRCA 1/2
- Somatic mutation testing along with limited NGS panel for MSI, TMB, dMMR, BRAF, NTRK, BRCA 1/2 in tissue, other homologous recombination repair genes**, LOH score
 - Consider comprehensive germline mutation panel
- Hereditary Ovarian Syndrome
 - Germline mutation testing
 - BRCA 1/2 negative – reflex to comprehensive NGS panel

Emerging

- Comprehensive NGS panel
- MRD

Regular monitoring including, but not limited to CEA, AFP, CA-125, LDH and CA19-9 is required as standard of care.

**CHEK2, BARD1, BRIP1, PALB2, RAD50, RAD51C, ATM, ATR, EMSY, Fanconi anemia genes, MMR genes,.

Ovarian

Advanced Disease or Progressed on Treatment (somatic)

When and what should be tested?

- Treatment eligible
- Stage IV, PS of ECOG 0-2
- Advanced disease or progression on treatment
- Patients with hereditary risk syndromes
- Tissue sample preferred
- Consider liquid biopsy if lack of tissue

FDA/NCCN approved

- BRCA 1/2 (to guide treatment selection)
- MSI-H/dMMR
- TMB
- NTRK
- ER
- HER2
- HRRm analysis/Loss of heterozygosity
- FR-alpha
- RET gene arrangement
- BRAF V600E
- HRD
- Hereditary Ovarian Syndrome
 - Germline mutation testing
 - BRCA 1/2 negative – reflex to comprehensive NGS panel
- Recurrent Disease
 - Somatic mutation testing along with limited NGS panel for MSI, TMB, dMMR, NTRK*, HRD, BRCA 1/2 in tissue, other homologous recombination repair genes**, LOH score, KRAS
 - Consider comprehensive germline mutation panel

Emerging

- Comprehensive NGS panel
- RAF, MEK, NaPi2b

Informational Considerations

- Cu isotope (serum), exosomes (ascites), lncRNA and mRNA, ALDH1, GSTP

Regular monitoring including, but not limited to CEA, AFP, CA-125, LDH and CA19-9 is required as standard of care.

**CHEK2, BARD1, BRIP1, PALB2, RAD50, RAD51C, ATM, ATR, EMSY, Fanconi anemia genes, MMR genes,.

cencora

©2024 IntrinsiQ Specialty Solutions, Inc. Confidential and proprietary. The content herein is subject to all license terms and restrictions between you and IntrinsiQ or its affiliates. This content is for the use and benefit of your organization only. All content is provided for informational purposes only. This content is not to be used as a substitute for professional training, clinical judgment or the applicable guidelines and protocols.

Uterine Cancer

Newly diagnosed disease

When and what should be tested?

- At diagnosis
- Tissue sample preferred
- Consider liquid biopsy if there is a lack of tissue

Who should be tested?

- All treatment eligible patients

FDA/NCCN Approved

- ER/PR for LMS, ESS, and adenosarcoma

Emerging

Uterine Cancer

Metastatic or Recurrent disease

When and what should be tested?

- At time of metastasis or disease recurrence
- Tissue sample preferred
- Consider liquid biopsy if there is a lack of tissue

Who should be tested?

- All treatment eligible patients

FDA/NCCN Approved

- ER/PR
- NTRK
- MSI/MMR
- TMB
- RET
- ALK
- BRCA
- HER2

Emerging

Endometrial Cancer

Newly diagnosed disease

When and what should be tested?

- At diagnosis
- Tissue sample preferred
- Consider liquid biopsy if there is a lack of tissue

Who should be tested?

- All treatment eligible patients

FDA/NCCN Approved

- ER/PR for stage III/IV
- HER2 for all p53 aberrant carcinomas regardless of histology
- POLE
- MMR
- MSI
- p53 by IHC

Emerging

Endometrial Cancer

Metastatic or Recurrent disease

When and what should be tested?

- At time of disease recurrence
- Tissue sample preferred
- Consider liquid biopsy if there is a lack of tissue

Who should be tested?

- All treatment eligible patients

FDA/NCCN Approved

- ER/PR
- HER2 for all p53 aberrant carcinomas regardless of histology
- POLE
- MMR
- MSI
- TMB
- NTRK
- p53 by IHC

Emerging